Back to articles

Higher-target hemoglobin levels not associated with improved quality of life from ESA use in kidney disease


Use of higher-target hemoglobin levels for erythropoietin-stimulating agents (ESAs) in patients with anemia associated with chronic kidney disease (CKD) did not result in improved health-related quality of life (QOL), according to a systematic review and meta-analysis published online in the Annals of Internal Medicine.